SI-BONE, Inc. (SIBN)

Over the past six months, SI-BONE's stock has experienced several notable events. As of February 6, 2026, the company's market capitalization was $676.48 million, reflecting a decrease of 17.28% over the past 30 days and 20.94% over the last 12 months. In December 2025, the market cap had increased by 26.11% from November 2025. SI-BONE exceeded Q3 2025 expectations, reporting an EPS of -$0.11 and revenue of $48.7 million, leading to a 0.89% after-hours stock increase. On January 12, 2026, SI-BONE announced preliminary fourth-quarter 2025 revenue between $56.2 million and $56.3 million. In December 2025, Needham raised its price target on SI-BONE to $27.00, and TD Cowen initiated coverage with a Buy rating and a $21.00 price target on January 26, 2026. Several executives engaged in stock sales between November 2025 and February 2026. In Q1 2025, the company updated its full-year revenue guidance to a range of $193.5 million to $197.5 million, which was further raised in Q2 2025 to a range of $195 million to $198 million.

SI-BONE experiences normal seasonality in demand, with a slight sequential revenue decline of 3-5% typically expected between the second and third quarters. The first quarter is also noted as a seasonally higher cash usage quarter. Macroeconomic uncertainty is not currently impacting procedure volumes.

SI-BONE, Inc. is a medical device company focused on musculoskeletal disorders of the sacropelvic anatomy, operating in the Healthcare sector, specifically in the Medical Devices and Healthcare Equipment & Supplies industry. They develop and commercialize minimally invasive surgical implant systems, including the iFuse Implant System® for sacroiliac (SI) joint fusion, iFuse-3D, iFuse TORQ, iFuse Bedrock Granite Implant System, and iFuse INTRA implants. The company markets its products through a direct sales force, third-party sales agents, and resellers.

SI-BONE, Inc. has a strong presence in North America and is expanding globally, commercializing its surgical implant systems in the United States and internationally.

SI-BONE has established itself as a leader in the SI joint and pelvic fixation markets. The company is recognized for its commitment to clinical excellence, continuous innovation, and providing a meaningful impact on patient outcomes, supported by clinical evidence including randomized controlled trials and peer-reviewed publications. No specific events negatively affecting SI-BONE, Inc.'s brand reputation in the past year were found in the provided search results.

SI-BONE, Inc. has 326 institutional owners and shareholders holding a total of 52,142,181 shares. Major institutional shareholders include BlackRock, Inc., American Century Companies Inc, Brown Advisory Inc, Orbimed Advisors LLC, Vanguard Group Inc, Champlain Investment Partners, LLC, First Light Asset Management, LLC, Silvercrest Asset Management Group LLC, and Nuveen, LLC. Institutions hold approximately 91.91% of the common stock.